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Abstract 
 
Background: There is abundant evidence of the comparative efficacy of single-
fraction (SF) radiotherapy and multi-fraction (MF) radiotherapy when treating patients 
with bone metastases. Despite this, previous surveys have shown SF schedules to 
be underutilised.  
Aim: To determine current patterns of practice in patients with bone metastasis and 
to investigate the factors that influence practice. 
Method: An electronic audit was performed amongst 46 physicians, within 7 hospital 
trusts in the UK. The audit comprised of 4 hypothetical cases in which consultants 
and registrars choose which dose and fractionation they would recommend and their 
reasons for this recommendation.  
Results: SF radiotherapy was the most common radiotherapy schedule in 
hypothetical cases 1, 3 and 4. SF radiotherapy was recommended by 65% of 
respondents in case 1, 47% in case 2, 89% in case 3 and 46% in case 4. For case 2, 
50% proposed MF radiotherapy. For case 4, 22% of respondents recommended 
SABR. The following deciding factors were cited as influencing choice of a SF 
schedule: prognosis, published evidence, performance status and spinal cord 
compression.  
Conclusion: The most common radiotherapy schedule selected was SF. However, 
there are inter-institution differences regarding the use of SF radiotherapy. 
Furthermore, the survey had shown that a third of respondents recommended a MF 
regime, despite evidence supporting the efficacy of a single fraction schedule. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
After lung and liver, the skeletal system is the most common location for metastasis 
(1). Skeletal metastases develop in 70-80% of patients with breast or prostate cancer 
and in up to 40% of patients with advanced stage lung cancer (2). 
Bone metastases can cause significant morbidity. The management of bone 
metastases depends upon location as well as patient performance status and 
previous treatment (1). Therapeutic options include: analgesics, systemic therapy, 
bisphosphonates and radiotherapy. The purpose of such treatments are to relieve 
pain and reduce risk of fractures. Treatments can also prevent problems linked with 
untreated progressive disease such as spinal cord compression (3).  
It has been found that 50% of cancer patients will have palliative radiotherapy during 
the course of their disease. Palliative radiotherapy has a 50-80% likelihood of overall 
pain relief (4).  
Randomised controlled trials have been carried out comparing single and multiple 
fractionated (SF and MF) regimes. Even though the findings have shown a 
comparative efficacy of both single and multiple fractionated schedules, it has been 
shown single fraction treatments remain underused (5; 6; 7; 8;9). 
The aim of this study is to carry out an audit of a number of radiotherapy 
departments and their current external beam radiotherapy regimes to investigate 
factors associated with the choice of dose and fractionation in the treatment of bone 
metastases. 
 
 
Ethical Issues 
Participants and their trusts were assured of their and their trusts anonymity and 
permission were granted from the managers at each department. Nine departments 
were contacted which had a partnership with Sheffield Hallam University. 
With regards to approval of this study, the Faculty of Health and Wellbeing Research 
Ethics Committee was consulted, and approval received (10).  
Once permission was gained, an email was sent to the consultants and registrars 
inviting them to take part.  
Materials and Method:  
An electronic audit was designed and performed amongst 46 physicians, within 7 
hospital trusts. The 7 trusts used were partnered with Sheffield Hallam University as 
part of their 9 current training sites. This was distributed using Survey Monkey 
(Survey Monkey Solutions, Dublin, Ireland). An advantage of an electronic audit is 
that they tend to acquire a greater response compared to postal surveys (11). 
The audit comprised of open and closed questions, 4 hypothetical cases of patients 
with bone metastases as well as general demographic questions. Population, 
Exposure and Outcome (PEO) and Population, Intervention, Comparison, Outcome 
(PICO) research models were used to help shape and define questions. 
The hypothetical cases used within the survey were adapted from previous studies 
to allow comparisons to be made (5; 6; 7;9). Table 1 describes the hypothetical cases 
that were used in the survey.  See Appendix 1 which shows the full survey. 
 
Case 1 A 55-year-old woman has metastatic 
breast cancer with evidence of disease 
in the liver. The bone scan shows 
increased uptake of radionuclide at T6-
T9. There is no evidence of spinal cord 
compression. Her ECOG performance 
status is 1.  
Case 2 A 55-year-old woman has metastatic 
non-small cell lung cancer. Radiologic 
examinations showed osteolytic bone 
metastasis at L3. There is evidence of 
mild vertebral collapse, with spinal cord 
compression on magnetic resonance 
imaging scan. Her ECOG performance 
status is 1. 
Case 3 A 70-year-old man has metastatic 
hormone-refractory prostate cancer. 
The bone scan shows an uptake within 
the left shoulder. On plain X-ray, there 
are ostetoblastic lesions without 
pathological fractures in the left 
shoulder. His ECOG performance 
status is 1. 
Case 4 A 68-year-old man has previously been 
treated for renal cancer with a 
nephrectomy. Two years later he 
presents with pain in his back in which 
the MRI scan shows a solitary 
metastasis on T12 with no evidence of 
spinal cord compression. His ECOG 
performance status is 2 
Table 1: Hypothetical cases 
Key: T= Thoracic; L= Lumbar; ECOG= Eastern Cooperative Oncology Group 
 
A pilot study was carried out in one of the clinical sites to test the survey and 
determine whether further development to the questionnaire was needed. Minor 
changes were introduced as a result of the pilot (12). 
Sampling  
The sampling method that was used was voluntary convenience sampling. 
Consultants and registrars in oncology were invited to participate via email.  
 
 Data analysis 
The data was analysed using the Statistical Package for Social Sciences (SPSS), 
version 24. There was a mixture of qualitative and quantitative questions used. The 
type of variable used established how the data was presented (13). Quantitative 
variables would include nominal or ordinal variables which can be presented using 
graphs to identify any patterns. In this case, the nominal variables were the number 
of consultants that prescribed a certain fraction for a hypothetical case. 
The data was represented using bar graphs (see fig 1 and 2.) so that comparisons 
could be made (13). In that, the radiation dose prescription that each consultant and 
registrar decided to prescribe were compared for each hypothetical case. The data 
was also presented in tables 2 and 3, so that cross-tabulation could occur.  
As categorical data was produced a chi-square test (x2) performed to test 
significance between two variables such as factors associated with the choice in 
fractionation (14). A P value lower than 0.05 was considered to indicate statistical 
significance. 
 
Discussion and Results. 
 
Single fraction vs. Multiple fractionated regime when treating bone metastases 
Studies have compared the efficacy of a SF to MF schedules when treating 
patients with bone metastases. In terms of MF regimes, they have varied from: 20 
Gy in 5 fractions, 24 Gy in 6 fractions, 30 Gy in 10 fractions and 40 Gy in 20 
fractions. The single fraction usually consists of either 6 Gy or 8 Gy (1). 
A systematic review and meta-analysis of the literature, which compared SF 
radiotherapy to a MF schedule for patients with bone metastases was completed by 
Sze et al.(8) in which eleven trials involving 3435 patients were identified. The 
findings had shown that the overall pain relief response rate was 60% for patients 
that had a SF and 59% for those that had a MF regime of radiotherapy. Confidence 
intervals were 0.89 to 1 which infers that were no differences in overall pain relief 
within the treatment schedules. The similarity between the treatment schedules 
regarding complete pain response implies that SF radiotherapy is as effective as 
multiple-fractionated radiotherapy, in terms of pain relief. Similar findings were 
shown by Arnalot et al. (15), Chow et al. (16) and Wu et al. (17). 
Strengths of a single fraction 
Another advantage of SF treatments was demonstrated by Hartsell et al. (18). Their 
results show that the SF schedule had less acute toxicity compared to the MF arm. 
This study only included patients with primary breast or prostate cancer which 
means outcomes may not be the same as other sites. However, Wu et al. (17) 
compared factors such as pain relief and acute toxicities across different tumour 
types and found that there was no significant difference in pain relief. Furthermore, 
the quality of life assessment did not show a difference between the single and 
multiple fractionation arms.  
Hartsell et al. (18) further highlighted that SF radiotherapy offers a major 
economic advantage of savings in radiotherapy capacity. However, reimbursement 
and health infrastructure are different in the US than in the UK, making it is difficult to 
apply these findings to the UK health care setting. Hartsell et al. (18) stated that fewer 
visits to the hospital would result in lower cost for the patient. 
Weaknesses of single fraction 
One of the main drawbacks of delivering palliative radiotherapy in a SF is the 
retreatment rate being higher than a multiple fractionated regime. Chow et al. (16) 
found that the retreatment rate was 2.6-fold greater in the SF arm, statistically 
significant (p=0.00001). The reasoning behind this could be due to the radiation 
oncologists being more willing to retreat patients when they have had a SF due to SF 
treatments being well within the limits of radiation tolerance (17,19,20). 
Another weakness of delivering the 8 Gy in a SF compared to MF schedule is 
the risk of a pathological fracture in the single fraction arm is greater (16). Though, the 
systematic review had shown that there was not a significant difference between the 
two when they had reviewed 10 trials that had reported pathological fracture rates. 
Despite the results not being statistically significant, there was a trend for lower rates 
in the multiple fractionation arm.  
Stereotactic Body Radiotherapy  
Stereotactic Body Radiotherapy (SABR) is a technique used to deliver a high dose of 
radiation to a target in a smaller number of fractions in comparison to conventional 
radiotherapy. This can provide better local control and longer symptom palliation in 
the setting of bone pain, compared to conventional radiation therapy. There are 
certain criteria that need to be met for SBRT treatment such as: well-circumscribed, 
inoperable lesion (21). Current published results suggest that we can use single-
fraction at up to 20 Gy for relief of acute bone pain (21). 
 
Studies to show patterns of practice 
In spite of the number of randomised controlled trials showing the efficacy of 
delivering radiotherapy in a single fraction (8; 15; 16; 17), there is a variation in practice 
on an international basis as well as differences between centres in the UK. For 
instance, a study distributed an electronic survey to radiation oncologists to find out 
their patterns of practice (5). The findings showed that the most prescribed schedule 
was 30 Gy in 10# emphasising a gap between evidence and practice. It also looked 
at the decision factors affecting dose prescription which allowed for comparisons to 
be made. In that, the oncologists were more likely to prescribe a shorter fractionation 
regime if the life expectancy of the patient was short. 
 As mentioned, patterns of practice may vary between radiotherapy centres. A 
review collated several trials to determine global patterns of practice (22). It was found 
that radiation oncologists from the United States (US) and Asia were less likely to 
deliver radiotherapy in a single fraction (range: 1-15.6% of hypothetical cases) 
whereas patients in Canada, Australia and from the United Kingdom were more 
likely to receive a SF (range: 10.9–38.9%). The variation in practice may be due to: 
oncologist preference, possibly influenced by reimbursement, patient age and the 
number of sites of bone metastases (23). It was concluded that a global reluctance 
still exists regarding the prescription of a single fraction of radiotherapy over the 20 
years they had studied (1993-2013) (22).  
 It was found that (24), the utilisation rate of single-fraction was below 5% 
despite the American Society for Radiation Oncology (ASTRO) guidelines, as a 
result ASTRO published new guidance in 2017 (25). This was due to new literature 
that had arisen since 2011 (16).  
For this research an audit was undertaken and aimed to show what factors 
influenced the consultants in the UK with the choice of prescribed dose and 
differences between centres in the UK. 
Aim/research question 
“An audit of current external beam radiotherapy regimes in parts of the UK to 
investigate factors associated with the choice of dose and fractionation in the 
treatment of bone metastases.” 
The literature review showed that there is a variation in patterns of practice when 
treating bone metastases despite there being abundant evidence and guidelines of 
the equivalence of SF to a MF regime. There are multiple factors that influence the 
choice of fractionation as discussed in the literature review. The recent publication by 
ASTRO (25) could influence patterns of practice and standardise the care of patients 
with bone metastases.  
A total of 46 clinical radiation oncologists returned responses. Seven out of the nine 
departments that work in partnership with Sheffield Hallam University took part in the 
audit. The distribution of the departments in the population of responders is shown in 
Figure 1. Of those responders, 39 were consultants and 7 were registrars.  
 
Figure 1: Distribution of responses  
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The recommended doses for cases 1 through to 4 are summarised in Figure 2. For 
case 1 and 3 the most commonly prescribed regimen was 8 Gy in 1#. Case 2 
described a patient with mild vertebral collapse with evidence of spinal cord 
compression. The results show that 47.83% of respondents would deliver 
radiotherapy in a single fraction. For oligometastasis (case 4), 22% of respondents 
would prescribe a high-dose multi-fraction radiotherapy.  
 
Figure 2: Fractionation schedule for each case 
 
Factors associated with the fractionation schedule used 
The results of the chi squared test had shown certain factors to have an influence on 
the fractionation schedule. Table 2 shows the factors that had a significant 
relationship between the single fraction and the factors for each case. 
 Performance 
status 
Published 
evidence  
Prognosis Site of 
metastasis 
Spinal cord-  
compression 
Case 1 1, N=46) = 
18.87, p= .001 
x2 (1, N=46) = 
17.49, p= .001 
(1, N=46) = 
9.58, p= .002) 
- - 
Case 2  
- 
(1, N=46) = 
3.994, p= .046) 
 
- 
(1, N=46) = 
3.994, p= .046) 
(1, N=46) = 
22.501, p= 
.001 
Case 3 1, N=46) = 
5.056, p= .025) 
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Case 4  
- 
(1, N=46) = 
3.673, p= .05) 
(1, N=46) = 
4.862, p= .027) 
(1, N=46) = 
4.018, p= .045) 
 
- 
Table 2: Significant factors influencing the decision of a single fraction 
 
Inter-institution Differences 
The results had shown that certain departments are more likely to choose a single 
fraction. Table 3 shows how many physicians at each department decided to 
prescribe 8 Gy in 1# for case 1. The physicians from department 9, all decided they 
would give a single fraction. Whereas, 66% of physicians at department 1 would 
choose the single fraction. Furthermore, the physicians at department 6 were more 
likely to choose a multi-fraction regime.  
For case 2, table 3, shows that, all of the physicians at department 1 would prescribe 
20 Gy in 5#. In comparison to this, all the physicians at department 4 and 5 would 
deliver radiotherapy in a single fraction. However, department 3,8 and 9 indicated 
differences within their departments.   
 
Table 3: Comparison of departments for cases 1,2,3 and 4 recommending 8 Gy in 1# 
 
Findings 
This survey was performed to demonstrate patterns of practice in patients with bone 
metastases and to determine the factors affecting radiotherapy prescriptions. The 
most commonly prescribed prescription was 8 Gy in 1#. However, multi fraction 
schedules are still being used. The factors influencing such decisions included: 
performance status, published evidence and site of metastasis. This varied 
depending on the hypothetical case. The factors least influencing such decisions 
were: department policy, finance, patient choice and patient age.  
Case 1 
The results had shown that the majority of consultants and registrars would use a SF 
(65.2%). This case was modified from a study, (6) to allow comparisons to be made. 
In fact, their results had shown that only 12.1% of all respondents recommended SF 
radiotherapy. This suggests that since 2009, an increased uptake in consultants 
preferred to use SF radiotherapy.  
Furthermore, there was a significant relationship between the use of 8 Gy in 1# and 
the influence of published evidence, x2 (1, N=46) = 17.49, p= .001. Having said that, 
there was also a significant relationship between 20 Gy in 5# and the influence of 
published evidence, x2 (1, N=46)= 11.576, P=.001.  
There was a significant relationship between SF radiotherapy and prognosis, x2 (1, 
N=46) = 9.58, p= .002. This is comparable to other studies such as: (5) who found 
that 69.3% of respondents felt that the prognoses of patients are a factor that would 
influence their decision. It was found that 46% of respondents would choose SF 
radiotherapy if the patient has a poor prognosis (3). A study (6) stated that stated that 
due to the limited survival of palliative patients, the use of SF radiotherapy is 
recommended, to decrease the time spent in medical appointments 
Case 1 involved disease at T6-T9. It is not feasible to use SABR to treat extensive 
multilevel disease that involves the spine (21). However, a respondent recommended 
a “SBRT type dose if she has oligometastatic disease”.  
Another respondent stated that, travelling distance can be a factor, but “other factors 
selected usually have more of an impact on choice of dose/fractionation”. As part of 
the reasoning from Lutz et al. (25) recommending the use of a SF, it was mentioned 
that a single 8 Gy fraction provides a none inferior pain relief compared to a MF 
regime, which can be convenient for patients with a poor prognosis. Patient 
convenience was an important factor when recommending the fractionation, in 3.4% 
of patients (5). This indicates that this is not one of the main factors in determining 
dose (5).  
Case 2 
For case 2, 22 respondents (47.83%) selected delivering a SF schedule whereas, 24 
respondents (52.17%) chose a multi-fractionated regime. Indicating differences in 
the dose prescription when patients have spinal cord compression. A comparable 
case about spinal cord compression was in a survey distributed in Italy (9). The 
results had shown that 30% of respondents would prescribe SF radiotherapy. The 
low use of SF radiotherapy was attributed to the perceived risk of cord compression 
and that neuropathic pain requires high doses to alleviate pressure on nerves. 
Nakamura et al. (7) included a comparable case within their study and the findings 
had shown that 79% of respondents would deliver using a multi-fractionated regime. 
However, a small sample size reduces reliability in this study. 
On the other hand, two respondents noted that “SCORAD trial results” influenced 
their decision of choosing a SF. Hoskin et al. (26) compared 8 Gy in 1# to multiple 
fractions for patients with spinal-cord compression and found that using a single 
dose of 8 Gy is as effective in terms of overall survival. Therefore, it is recommended 
to use a single dose in this setting, with the main benefit of requiring a single visit.  
In terms of the factors influencing the respondent to choose a SF, there was a 
significant relationship between spinal cord compression and delivering a single 
fraction, x2 (1, N=46) = 22.501, p= .001. Also, there was a significant relationship 
between published evidence and delivering a single fraction, x2 (1, N=46) = 3.994, 
p= .046.  
Case 3 
Case 3 described a hormone-refractory prostate cancer patient, who presented with 
progression of pain which was found to be osteoblastic lesions in the left shoulder. 
The findings had shown that 89.3% of responded would choose SF radiotherapy. 
The survey distributed by Fairchild et al. (6) had a comparable case which was also 
found to have 8 Gy in 1# as the most common regimen. There was a significant 
relationship between prognosis and delivering a SF as p=0.01. This is because of 
the limited survival of patients and the importance of decreasing the time invested in 
hospital appointments (6). 
A respondent chose to deliver a SF schedule but stated the increased likelihood of 
retreatment due to this. As mentioned, Chow et al. (16) found that the retreatment rate 
was 2.6-fold greater in the SF arm compared to MF. However, this could be due the 
radiation oncologists being more willing to retreat patients as the sum of both 
treatments would be within the limits of radiation tolerance (17).  
Case 4 
Finally, case 4 describes a patient with a solitary metastasis on T12 who had 
previously been treated for renal cancer. Twenty-one (46.67%) respondents chose 
SF radiotherapy. There was a significant relationship between 8 Gy in 1# and poorer 
prognosis compared to MF regimes x2 (1, N=46) = 4.862, p= .027. Therefore, 
consultants are more likely to prescribe 8 Gy in 1# as a result of prognosis. Again, 
published evidence was a significant factor influencing respondents to choose SF 
radiotherapy, x2 (1, N=46) = 3.673, p= .05.  
In terms of multi-fraction radiotherapy, 14 respondents (30%) recommended this. In 
that, 8 respondents chose 30 Gy in 10# and 6 respondents chose 20 Gy in 5#.  
However, ten (22.22%) respondents suggested a SABR dose due to it being a 
solitary metastasis. Nakamura et al. (7) had a comparable case about 
oligometastasis, in which 15/52 (29%) respondents recommended a high dose. 
Jhaveri et al. (21) looked at SABR for bone metastases to investigate the impact of 
high doses at a target using single or multiple doses. It was found that SBRT can be 
safe and effective in relieving bone pain from metastatic disease. Current published 
results have shown that SF-SBRT of up to 20 Gy can be used to relieve bone pain 
(21). One of the respondents suggested a dose of 20Gy in 5# and mentioned that it is 
a resistant disease. However, Jhaveri et al. (21) stated that doses of up to 20Gy can 
also be used for radioresistant tumour types such as renal cell carcinoma. The 
implications of this is that, in the future the use of SABR may increase due to the 
positive findings studies have shown. 
Inter-institution differences 
As mentioned, certain departments are more likely to deliver SF radiotherapy such 
as departments 4, 5 and 6 (see table 3).  
In terms of the frequency of respondents of each departments suggesting SABR for 
case 4 in a SF, there were 4, 3,2,1 number of respondents from department 1,4,8 
and 3 respectively. This could be due to the increased use of SABR within these 
departments. 
Limitations 
Limitations include the primary researchers lack of experience in this type of 
research. 
Another limitation was the small sample size. Due to the small absolute sample size 
(n = 46), the results might not accurately represent the practice of physicians in the 
UK. Previous studies regarding patterns of practice with patients that have bone 
metastases have stated the response rate of the health professionals involved in 
their studies have been low which can affect the validity and reliability of their 
findings. Magne et al. (3) had a response rate of 15.7% and Nakamura et al.’s (7) 
study had a response rate of 36%.  
 
 
 
Conclusion 
This survey has shown that the results tally with recent guideline recommendations 
(25). In that, the majority of respondents recommended a SF to treat patients with 
bone metastases. The factors which had influenced the consultants and registrars to 
choose a SF schedule were: published evidence, prognosis, performance status and 
spinal cord-compression. The factors considered the least often were: patient choice, 
finance, late side effects and department protocol. But, about a third of respondents 
indicated use of MF regimes. The use of SABR may increase in the future due to 
studies supporting the its use in a palliative setting for patients with solitary 
metastases.  
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Appendix 1 
1) What department do you work in? 
N.B The question allows data to be collated for analysis but the name of the centre will be 
anonymised when the findings are being carried out  
  
Case 1: 
A 55-year-old woman has metastatic breast cancer with evidence of disease in the liver. The 
bone scan shows increased uptake of radionuclide at T6-T9. There is no evidence of spinal 
cord compression. Her ECOG performance status is 1. Abbreviation: ECOG = Eastern 
Cooperative Oncology Group.Assume that you decide to give external beam radiotherapy, 
what dose and fractionation would you give? 
 
Assume that you decide to give external beam radiotherapy, what dose and fractionation 
would you give?  
 8Gy in 1# 
 20Gy in 5# 
 30Gy in 10# 
 Other dose. Please specify:   
Please tick all boxes that would influence your choice of dose and fractionation, for this case 
and similar cases. 
 Performance status  
 Site of metastasis 
 Patient age 
 Patient choice 
 Financial aspects 
 Published evidence.  
 Late Side effects 
 Spinal cord compression (present or impending) 
 Prognosis  
 Departmental protocol 
 Other. Please specify: 
 
 
 
 
Case 2: 
A 55-year-old woman has metastatic non-small cell lung cancer. Radiologic examinations 
showed osteolytic bone metastasis at L3. There is evidence of mild vertebral collapse, with 
spinal cord compression on magnetic resonance imaging scan. Her ECOG performance 
status is 1. Assume that you decide to give external beam radiotherapy, what dose and 
fractionation would you give? 
Same layout as case 1 
Case 3: 
A 70-year-old man has metastatic hormone-refractory prostate cancer. The bone scan 
shows an uptake within the left shoulder. On plain X-ray, there are ostetoblastic lesions 
without pathological fractures in the left shoulder. His ECOG performance status is 
1.Assume that you decide to give external beam radiotherapy, what dose and fractionation 
would you give? 
Same layout as case 1 
Case 4: 
A 68-year-old man has previously been treated for renal cancer with a nephrectomy. Two 
years later he presents with pain in his back in which the MRI scan shows a solitary 
metastasis on T12 with no evidence of spinal cord compression. His ECOG performance 
status is 2. Assume that you decide to give external beam radiotherapy, what dose and 
fractionation would you give? 
Same layout as case 1 
 
Abbreviation: ECOG = Eastern Cooperative Oncology Group. 
T= Thoracic 
L= Lumbar  
 
